Physician profile
Daniel L Taylor
NPI 1134201494
$14,020.54
in general payments reported to CMS, 2019-2025
32 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,529 · 2020: $1,695 · 2021: $2,791 · 2022: $1,757 · 2023: $1,768 · 2024: $821 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,249.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,962.68 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,709.75 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,282.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,140.02 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $1,130.42 | 2021-2023 | Nuzyra |
| Glaxosmithkline, LLC. | $780.49 | 2020-2025 | Arexvy |
| Arbor Pharmaceuticals, INC. | $672.74 | 2019-2021 | |
| Amgen INC. | $662.73 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $618.51 | 2019-2025 | Mounjaro, Jardiance |
| Boston Scientific Corporation | $505.92 | 2020-2022 | |
| Pfizer INC. | $423.10 | 2019-2024 | |
| Amarin Pharma, INC. | $372.53 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $321.09 | 2019-2021 | |
| Ibsa Pharma INC. | $285.86 | 2021-2024 | Tirosint, Licart, Flector |
| Mallinckrodt Hospital Products INC. | $263.70 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $260.30 | 2019-2021 | |
| Genentech USA, INC. | $182.85 | 2019-2021 | |
| Electromed, INC. | $172.00 | 2019-2024 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $162.28 | 2019-2020 | |
| Gilead Sciences, INC. | $147.51 | 2019 | |
| Abbott Laboratories | $145.76 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $131.90 | 2019 | |
| Genzyme Corporation | $122.94 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.73 | 2019 | |
| Edwards Lifesciences Corporation | $101.66 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vifor Pharma, INC. | $89.50 | 2019 | |
| Exact Sciences Corporation | $75.49 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $45.20 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $44.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.25 | 2019 | |
| Allergan, INC. | $28.39 | 2020 | |
| Nabriva Therapeutics, Plc | $20.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.